KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.

Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Huamao M Lin, Robert J Fram, Tony S K Mok

J Clin Oncol 43(13) 1553-1563

PMID39879577
PMCIDPMC12054980
DOI10.1200/JCO-24-01269
发表日期2025-01-29
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2, ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of EGFR ex20ins+ advanced/metastatic NSCLC. METHODS: Patients with treatment-naive EGFR ex20ins+ locally advanced/metastatic NSCLC were randomly assigned 1:1 to mobocertinib 160 mg once daily or pemetrexed plus cisplatin or carboplatin every 3 weeks for four cycles followed by maintenance pemetrexed. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR), with planned interim analysis (IA) after approximately 70% of 227 expected PFS events. RESULTS: A total of 354 patients were randomly assigned (mobocertinib: n = 179; chemotherapy: n = 175). Baseline characteristics were balanced between arms. At IA (cutoff: April 4, 2023), the median PFS per BICR was 9.6 months in each treatment arm (hazard ratio [HR], 1.04 [95% CI, 0.77 to 1.39]; P = .803). The primary end point crossed the prespecified futility boundary (HR > 1). The confirmed objective response rate (95% CI) per BICR was 32% (26 to 40) with mobocertinib versus 30% (24 to 38) with chemotherapy; the median duration of response was 12.0 versus 8.4 months. Quality-of-life assessments indicated clinically meaningful delays in time to deterioration of lung cancer symptoms, cognitive function, and constipation with mobocertinib versus chemotherapy. Grade ≥3 adverse events in >5% of patients (mobocertinib, chemotherapy) were diarrhea (20%, 1%), anemia (6%, 10%), increased lipase (6%, 0%), and decreased neutrophil count (1%, 7%). CONCLUSION: The EXCLAIM-2 trial did not meet its primary end point. The efficacy of mobocertinib was not superior to platinum-based chemotherapy for first-line treatment of patients with EGFR ex20ins+ advanced/metastatic NSCLC.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

FIG 2. Efficacy of first-line mobocertinib versus platinum-based chemotherapy in patients with EGFR ex20ins+ NSCLC. (A) Kaplan-Meier–estimated PFS by BICR assessment in the ITT population. (B) Forest plot of HRs for BICR-assessed PFS across patient subgroups. HRs are based on an unstratified Cox proportional hazards regression model. (C) DoR in confirmed responders. (D) OS in the ITT population. a <1 HR for treatment indicates better prevention of progression or death in the mobocertinib arm compared with the chemotherapy arm. BICR, blinded independent central review; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; EGFR ex20ins, epidermal growth factor receptor exon 20 insertion; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; NSCLC, non–small cell lung cancer; OS, overalll survival; PFS, progression-free survival.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DoR

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIG 2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

FIG 3.

FIG 3. TTD in patient-reported lung cancer symptoms. TTD in the EORTC QLQ-LC13 composite lung cancer symptom score (cough, dyspnea, and chest pain). A clinically meaningful change was defined as an 11.1-point (for dyspnea) or 33.3-point (for cough or chest pain) deterioration for the EORTC QLQ-LC13 composite score scale. EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; NE, not estimable; QLQ-LC13, quality-of-life questionnaire-lung cancer 13; TTD, time to deterioration.

Deterioration_Free_of_patients_

time to deterioration

FIG 3. · Panel Deterioration_Free_of_patients_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Deterioration_Free_of_patients_ 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram for the EXCLAIM-2 trial. Data are reported as of the cutoff date for the interim analysis (April 4, 2023). AE, adverse event; PD, progressive disease.
非 KM Figure